Our Chief Scientific Officer and Co-Founder here at Deep Lens, TJ Bowen, recently wrote this article for Drug, Discovery and Development.
How AI technology can democratize clinical trials in oncology
While the number of cancer treatments has nearly quadrupled in that time period from 421 to 1,489, cancer drugs take 30–40% longer than other indications to gain approval and 80% of oncology clinical trials fail to meet enrollment timelines.
Additionally, drug development has evolved tremendously — specifically, it has moved away from systemic chemotoxic agents and radiation to a focus on the development of drugs tailored to attack specific genetic defects present in cancer cells.
Here’s how AI-enabled software can help: